bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 16763: Complete Heart Block as a Complication of Diffuse Large B Cell Lymphoma
Authors: Luna Alvarez Amezquita Jose A , Becerra Victor G , Vazquez Moises A , PEREZ TAGLE TEJEDA ALFREDO , Palatianos de Araujo Yoana , Mijares Ivan A , Calfa Marian 
Published: December 2023

Abbreviations: DLBCL (diffuse large B cell lymphoma), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone).
Description of case
We present the case of a 78-year-old female who presented initially with a right neck mass, abdominal pain, diarrhea, and recurrent pericardial effusions requiring pericardial window procedure.
Biopsy of the neck mass demonstrated a DLBCL. Involvement of a right atrial mass attached to the septum in close relation to the tricuspid valve was seen on TEE. Metastatic disease to the lungs and liver was demonstrated on CT chest and abdomen respectively.
The patient posteriorly developed symptomatic bradycardia that on electrocardiogram and telemetry monitoring was shown to be due to a complete heart block with junctional and ventricular escape beats with a rate of 30-40 beats per minute. Due to the anatomical characteristics of the right atrial mass, placement of a right ventricle leadless pacemaker (micra) was decided. The patient was started on mini-CHOP chemotherapy shortly afterwards.
Discussion
Primary cardiac lymphomas are a rare presentation accounting for less than 1% of all cardiac malignancies. Although rare, secondary involvement of the heart is more frequent than primary involvement and represents 20-25% of the cases. From all the broad subtypes of lymphomas, DLBCL is the most commonly found to affect the cardiac system, often being represented by alterations in the conduction system and causing congestive heart failure.
The exact mechanism of the conduction abnormalities in the setting of cardiac lymphoma has not yet been well elucidated but is presumed to be either caused by an infiltration of the conduction system, direct mass burden effect, or a combination of both.
It has been seen in similar cases that initiation of chemotherapy can help decrease the pacing requirements or even resolve completely the conduction abnormalities. In a few cases, permanent pacing is required. Metastatic disease to the heart is a marker for poor outcome and median survival with therapy after diagnosis is between 7 to 18 months.
Abstract 17593: Betel Quid Addiction Causing Monomorphic Ventricular Tachycardia
Authors: Clark Cali , Miller Shane , Wilberding Justin 
Published: December 2023

A 44-year-old woman presented to the emergency room due to worsening shortness of breath over the past few days with accompanying dizziness, cough, and fever. Her history was significant for asthma, obstructive sleep apnea, and hypertension. Upon arrival, she was noted to be hypoxic on room air and required supplemental oxygen. Physical exam showed extensive pitting edema in the lower extremities and crackles in bilateral lung fields. Chest radiograph revealed an enlarged cardiac silhouette and increased interstitial infiltrates consistent with pulmonary edema. While in the emergency department she was noted to have frequent episodes of asymptomatic non-sustained monomorphic ventricular tachycardia. Further questioning revealed the patient had been using betel quid daily for over 20 years to improve her mood and energy levels. She had attempted to quit in the past but was unable to do so. Echocardiogram was performed which showed preserved left ventricular function and severely dilated right ventricle. BNP was elevated at 1930 pg/mL. Due to her ventricular arrhythmias and cardiomyopathy, coronary angiography was performed; this was negative for epicardial coronary artery obstruction. Case was discussed with electrophysiology who determined the arrhythmias were likely caused by the extensive betel quid consumption. She was placed on beta-blockers and betel quid cessation was strongly recommended.
Betel quid is a chewing product made from of areca nut, betel leaf, slaked lime, with or without tobacco. It is commonly used in the tropical Pacific, Asia, and parts of East Africa, and is the fourth most widely consumed addictive substances in the world due to its ability to increase alertness and produce mild euphoria. Adverse effects of betel quid include tachycardia, hyperlipidemia, metabolic syndrome, hepatotoxicity, and it is a known carcinogen. The active compound is arecoline, which acts as a parasympathomimetic on muscarinic and cholinergic receptors, increasing the central sympathetic response and producing tachycardia. Betel quid has been shown to produce ventricular arrhythmias in patients with underlying cardiomyopathy, which is likely what occurred in our patient. Betel quid cessation therefore advised in these patients.
Abstract 17883: Subacute Native Aortic and Mitral Valve Endocarditis Manifesting as Embolic ST-Elevation Myocardial Infarction
Authors: sreedhara karthik , Nasser Jason , McGervey Megan 
Published: December 2023

Case description:
A 54-year-old male presented with one day of substernal chest pain. He also reported two months of malaise, myalgias, chills, and intermittent fevers. Medical history was notable for well-controlled hypertension and negative for dyslipidemia, diabetes, or drug and tobacco use. Family history was negative for premature coronary artery disease.

Vitals were notable for fever of 103F, blood pressure of 108/56 mmHg, and heart rate of 88 beats per minute. Physical exam showed bounding pulses and a soft diastolic murmur at the left lower sternal border.
Electrocardiogram showed inferior lead ST-elevations. He was taken for cardiac catheterization and found to have a totally occlusive thrombus in the distal right coronary artery with minimal disease in the remaining vessels. He underwent aspiration thrombectomy and placement of drug eluting stent with normal flow. He was transferred to the coronary intensive care unit.
Labs showed mild leukocytosis, normal serum creatinine, and unremarkable urinalysis. Echocardiogram showed a 1.7 x 0.5 cm mobile echodensity on the aortic valve with severe aortic regurgitation and a small echodensity on the anterior mitral leaflet. Blood cultures grew Enterococcus faecalis. A CT scan of the head, chest, abdomen, and pelvis revealed no embolic disease.
He underwent urgent surgery due to concern for infective endocarditis with coronary embolism. Purulence was found at the stent site and the posterior descending artery was obliterated by necrotic tissue. A bypass graft was placed distal to the stent site and infected territory was unroofed and irrigated. Mitral and aortic valve replacement was performed. He tolerated surgery and was discharged with 6 weeks of intravenous antibiotics.

Discussion:
This case was unique in the subacute chronicity of endocarditis and lack of other systemic emboli. Clinically relevant coronary embolism was reported in only 1.5% of cases of infective endocarditis but microemboli were found in 60% postmortem. Embolization is more common with mitral valve involvement, >10 mm vegetation, and fungal or staphylococcal disease. Angiographic evidence of heavy thrombus burden or lack of significant atherosclerosis after myocardial infarction may prompt evaluation for coronary embolism.
Beckett personnage de roman
Authors: Mével Yann 
Published: December 2023

Résumé
Cet article vise à rendre compte des représentations de Samuel Beckett, en tant qu’homme et écrivain, et des usages fictionnels de sa vie, dans trois romans publiés en France, entre 2013 et 2020 : Gaby et son maître, d’Arthur Bernard, L’Apiculture selon Samuel Beckett, de Martin Page, et Le Tiers Temps, de Maylis Besserie. Ces fictions biographiques prennent plus ou moins ouvertement Samuel Beckett pour objet tout en recourant à l’imagination dans des proportions et selon des modalités variables. Notre étude, diachronique, se veut sensible à la singularité du projet porté par chacun de ces romans.
Ratio emblematum: Characteristic Features of the Jesuit Emblem
Authors: Melion Walter S. 
Published: December 2023

Abstract
The introductory essay examines the principles of Jesuit emblematic usage, as codified by Antonio Possevino, S.J. (1533–1611) in his educational treatise Bibliotheca selecta de ratione studiorum of 1603 and developed by two of the Society’s key emblematists: Jan David, S.J. (1545–1613) in his Duodecim specula of 1610 and Herman Hugo, S.J. (1588–1629) in his Pia desideria of 1624. The essay concludes by summarizing the five articles contained in this issue of the Journal of Jesuit Studies and then, on that basis, offering a brief account of the state of the question in the study of Jesuit emblematics.
The Emblematic Decoration of the Staircase at the Former Jesuit College of Győr in the Context of Jesuit Marian Iconography
Authors: Kusler Ágnes 
Published: December 2023

Abstract
This article contextualizes the emblematic decoration of the main staircase at the Jesuit College in Győr, northwestern Hungary. Painted in 1697, this fresco cycle visualizes the prayer of Salve Regina. The staircase emblems were designed as a visual aid to the Jesuits who wished to meditate on the significance of the Virgin Mary. Earlier scholarship has connected the decorative scheme to Jesuit emblem literature in general. In this article, I argue that the visual source of the program can be identified as the Salve Regina print series by Anton Wierix (1598). The emblems and their program, key examples of applied emblematics, demonstrate how and to what degree Jesuit meditative praxis underlay the decoration of Győr college. Focusing on the practical function of the decorative program also expands our knowledge of early modern practices of emblematic meditation in religious communities. This article is part of the special issue of the Journal of Jesuit Studies on Jesuit emblems and emblematic edited by Walter S. Melion.
Kurdish Queer Studies
Authors: Sandal-Wilson Hakan 
Published: December 2023

Abstract
This special issue introduction aims to map out encounters between Kurdish Studies and Queer Studies. While the growing scholarship on Queer Studies in the Middle East offers theoretically and politically significant frameworks and analyses, Kurdish experiences and interventions are notably absent from this picture. As well as outlining the contributions to the special issue, this introduction offers reflections on how Kurdish Studies, Middle East Studies, and Queer Studies would benefit from a “Kurdish Queer” perspective. In doing so, the introduction and this special issue more widely mark a shift from “queer encounters in Kurdish Studies” to “Kurdish Queer Studies” as an emerging field of inquiry, without setting rigid boundaries around it.
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
Authors: Phillips Tycel J. , Avigdor Abraham , Gurion Ronit , Patti Caterina , Corradini Paolo , Tani Monica , Mehta Amitkumar , Lossos Izidore S. , Zinzani Pier Luigi , Thieblemont Catherine , Jurczak Wojciech , Zheng Fred , Rappold Erica , Zhao Wanying , Jiang Ping , Johnson Peter 
Published: December 2023

Abstract
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell lymphomas. The phase 2 CITADEL-204 study (NCT03144674, EudraCT 2017-000970-12) assessed efficacy and safety of parsaclisib in Bruton tyrosine kinase (BTK) inhibitor–experienced (cohort 1) or BTK inhibitor–naive (cohort 2) patients with R/R marginal zone lymphoma (MZL). Patients aged ≥18 years with histologically confirmed R/R MZL, treated with ≥1 prior systemic therapy (including ≥1 anti-CD20 antibody) received parsaclisib 20 mg once daily for 8 weeks then 20 mg once weekly (weekly dosing group [WG]) or parsaclisib 20 mg once daily for 8 weeks then 2.5 mg once daily (daily dosing group [DG]); DG was selected for further assessment. Primary end point of the study was objective response rate (ORR). Owing to slower than expected recruitment, cohort 1 was closed with 10 patients (WG, n = 4; DG, n = 6) enrolled. Based on a planned interim analysis in cohort 2, the futility boundary was not crossed, and enrollment continued to study completion. At data cutoff (15 January 2021), 100 patients were enrolled and treated in cohort 2 (WG, n = 28; DG, n = 72). In the DG, the ORR was 58.3% (95% confidence interval [CI], 46.1-69.8), with a complete response rate of 4.2% (95% CI, 0.9-11.7); the lower bound of the ORR 95% CI exceeded the protocol-defined threshold of 40%. The median duration of response was 12.2 months (95% CI, 8.1-17.5) and progression-free survival was 16.5 months (95% CI, 11.5-20.6); median overall survival was not reached. The most common treatment-emergent adverse events (TEAEs) among all patients were diarrhea (47.0%), cough (23.0%), and rash (18.0%); the most common grade ≥3 TEAEs included diarrhea (12.0%), neutropenia, and pneumonia (9.0% each). TEAEs led to dose interruptions, reductions, and discontinuations in 56.0%, 16.0%, and 29.0% of all patients, respectively. Durable responses and an overall manageable safety profile were demonstrated in patients with R/R MZL treated with parsaclisib monotherapy.
Choosing the right mouse model: comparison of humanized NSG and NBSGW mice for in vivo HSC gene therapy
Authors: Choo Seunga , Wolf Carl B. , Mack Heather M. , Egan Mitchell J. , Kiem Hans-Peter , Radtke Stefan 
Published: December 2023

Abstract
In vivo hematopoietic stem cell (HSC) gene therapy is an emerging and promising area of focus in the gene therapy field. Humanized mouse models are frequently used to evaluate novel HSC gene therapy approaches. Here, we comprehensively evaluated 2 mouse strains, NSG and NBSGW. We studied human HSC engraftment in the bone marrow (BM), mobilization of BM-engrafted HSCs into circulation, in vivo transduction using vesicular stomatitis virus glycoprotein–pseudotyped lentiviral vectors (VSV-G LVs), and the expression levels of surface receptors needed for transduction of viral vectors. Our findings reveal that the NBSGW strain exhibits superior engraftment of human long-term HSCs compared with the NSG strain. However, neither model resulted in a significant increase in circulating human HSCs after mobilization. We show that time after humanization as well as human chimerism levels and platelet counts in the peripheral blood can be used as surrogates for human HSC engraftment in the BM. Furthermore, we observed low expression of the low-density lipoprotein receptor, a requirement for VSV-G LV transduction, in the human HSCs present in the murine BM. Our comprehensive characterization of humanized mouse models highlights the necessity of proper validation of the model and methods to study in vivo HSC gene therapy strategies.
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines
Authors: Ghilardi Guido , Paruzzo Luca , Svoboda Jakub , Chong Elise A. , Shestov Alexander A. , Chen Linhui , Cohen Ivan J. , Gabrielli Giulia , Nasta Sunita D. , Porazzi Patrizia , Landsburg Daniel J. , Gerson James N. , Carter Jordan , Barta Stefan K. , Yelton Rebecca , Pajarillo Raymone , Patel Vrutti , White Griffin , Ballard Hatcher J. , Weber Elizabeth , Napier Ellen , Chong Emeline R. , Fraietta Joseph A. , Garfall Alfred L. , Porter David L. , Milone Michael C. , O’Connor Roderick , Schuster Stephen J. , Ruella Marco 
Published: December 2023

Abstract
Lymphodepletion (LD) is an integral component of chimeric antigen receptor T-cell (CART) immunotherapies. In this study, we compared the safety and efficacy of bendamustine (Benda) to standard fludarabine/cyclophosphamide (Flu/Cy) LD before CD19-directed, CD28-costimulated CART axicabtagene ciloleucel (axi-cel) for patients with large B-cell lymphoma (LBCL) and follicular lymphoma (FL). We analyzed 59 patients diagnosed with LBCL (n = 48) and FL (n = 11) consecutively treated with axi-cel at the University of Pennsylvania. We also analyzed serum samples for cytokine levels and metabolomic changes before and after LD. Flu/Cy and Benda demonstrated similar efficacy, with complete remission rates of 51.4% and 50.0% (P = .981), respectively, and similar progression-free and overall survivals. Any-grade cytokine-release syndrome occurred in 91.9% of patients receiving Flu/Cy vs 72.7% of patients receiving Benda (P = .048); any-grade neurotoxicity after Flu/Cy occurred in 45.9% of patients and after Benda in 18.2% of patients (P = .031). In addition, Flu/Cy was associated with a higher incidence of grade ≥3 neutropenia (100% vs 54.5%; P &lt; .001), infections (78.4% vs 27.3%; P &lt; .001), and neutropenic fever (78.4% vs 13.6%; P &lt; .001). These results were confirmed both in patients with LBCL and those with FL. Mechanistically, patients with Flu/Cy had a greater increase in inflammatory cytokines associated with neurotoxicity and reduced levels of metabolites critical for redox balance and biosynthesis. This study suggests that Benda LD may be a safe alternative to Flu/Cy for CD28-based CART CD19-directed immunotherapy with similar efficacy and reduced toxicities. Benda is associated with reduced levels of inflammatory cytokines and increased anabolic metabolites.
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Authors: Bataller Alex , Bazinet Alexandre , DiNardo Courtney D. , Maiti Abhishek , Borthakur Gautam , Daver Naval G. , Short Nicholas J. , Jabbour Elias J. , Issa Ghayas C. , Pemmaraju Naveen , Yilmaz Musa , Montalban-Bravo Guillermo , Takahashi Koichi , Loghavi Sanam , Garcia-Manero Guillermo , Ravandi Farhad , Kantarjian Hagop M. , Kadia Tapan M. 
Published: December 2023

Abstract
Hypomethylating agents (HMAs) and venetoclax (Ven) represent the standard of care for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. However, the European LeukemiaNet (ELN) risk classifications have been validated for patients treated with intensive therapy. In this study, we validate a recently proposed new molecular prognostic risk signature (mPRS) for patients with AML treated with HMAs and Ven. This classification allocated patients to favorable, intermediate (N/KRAS or FLT3–internal tandem duplication mutations), and lower (TP53 mutations) benefit groups. We retrospectively analyzed 159 patients treated with HMA and Ven. The mPRS classification allocated 74 (47%), 31 (19%), and 54 (34%) patients to the higher, intermediate, and lower-benefit groups, respectively. The overall response rate was 71% (86%, 54%, and 59% in the higher, intermediate, and lower-benefit groups, respectively). The median overall survival (OS) and event-free survival (EFS) times were 30 and 19 months, respectively, in the higher-benefit group; 12 and 8 months in the intermediate-benefit group; and 5 and 4 months in the lower-benefit group (P &lt; .001). The C-index for OS and EFS was higher when stratifying patients according to mPRS classification than with the ELN 2022 classification. The 2-year cumulative incidence of relapse was 35%, 70%, and 60% in the higher, intermediate, and lower-benefit groups, respectively (P = .005). The mPRS classification accurately segregated groups of patients with AML treated with HMA plus Ven. In these patients, N/KRAS and TP53 mutations appear to negatively affect outcomes; therefore, new treatment approaches are warranted.
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
Authors: Jerkeman Mats , Kolstad Arne , Hutchings Martin , Pasanen Annika , Meriranta Leo , Niemann Carsten Utoft , Kragh Jørgensen Rasmus Rask , El-Galaly Tarec Christoffer , Riise Jon , Leppä Sirpa , Christensen Jacob Haaber , Sonnevi Kristina , Pedersen Lone Bredo , Wader Karin Fahl , Glimelius Ingrid 
Published: December 2023

Abstract
Despite improvements in treatment of mantle cell lymphoma (MCL), most patients eventually relapse. In this multicenter phase 1b/2 trial, we evaluated safety and efficacy of minimal residual disease (MRD)–driven venetoclax, lenalidomide, and rituximab (venetoclax-R2) in relapsed/refractory (R/R) MCL and explored the feasibility of stopping treatment in molecular remission. The primary end point was overall response rate (ORR) at 6 months. After dose escalation, the recommended phase 2 dose was lenalidomide 20 mg daily, days 1 to 21; venetoclax 600 mg daily after ramp-up; and rituximab 375 mg/m2 weekly for 4 weeks, then every 8 weeks. MRD monitoring by RQ-PCR was performed every 3 months. When MRD-negativity in the blood was reached, treatment was continued for another 3 months; if MRD-negativity was then confirmed, treatment was stopped. In total, 59 patients were enrolled, with a median age of 73 years. At 6 months, the ORR was 63% (29 complete remission [CR], 8 partial remission [PR]), and 40% (4 CR, 2 PR) for patients previously failing a Bruton tyrosine kinase (BTK) inhibitor. Median progression-free survival (PFS) was 21 months, with median overall survival of 31 months. TP53 mutation was associated with inferior PFS (P &lt; .01). Overall, 28 patients (48%) discontinued treatment in molecular remission, and 25 remain MRD negative after a median of 17.4 months. Hematological toxicity was frequent, with 52 of 59 (88%) patients with G3-4 neutropenia and 21 of 59 (36%) patients with G3-4 thrombocytopenia. To conclude, MRD-driven venetoclax-R2 is feasible and tolerable and shows efficacy in R/R MCL, also after BTK inhibitor failure. This trial was registered at www.ClinicalTrials.gov as #NCT03505944.
Why and how should children be protected from the deluge of vaping related media and marketing overexposure?
Authors: White David , Bush Andrew , Smyth Alan R. , Bhatt Jayesh Mahendra 
Published: December 2023

E-cigarettes are products delivering nicotineviainhalation and are devised to mimic tobacco smoking. While they were initially introduced as a device putatively to aid with smoking cessation, their use is now far broader than that. Use by children is significantly increasing. There is growing evidence of the potential harms of vaping. E-liquids used for e-cigarettes contain a wide range of harmful substances, and the clinical consequences of this are now being increasingly demonstrated, such as the rise in cases of e-cigarette- or vaping-associated lung injury. In addition, early use may result in long-term nicotine addiction. Vaping companies utilise marketing methods that distinctly target young people, and weak legislation in the UK allows them free rein to expose children to vaping.In this review we demonstrate why children must be protected from vaping. We must have stringent legislation to prevent easy access to e-cigarettes, including banning the convenience and affordability disposable vapes provide, and prevent marketing that does not warn about the potential health effects. The Australia approach of prescription or pharmacy only access for smoking cessation should be considered to limit exposure of children and minimise use by nonsmokers.